Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine for Tardive Dyskinesia
NCT00164242Phase 4Completed
- Start
- Jan 2002
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of galantamine in tardive dyskinesia (TD) (2 arms). Primary endpoint: Abnormal Involuntary Movement Scale at 3 months. Started Jan 2002; status: completed.
02
Drugs
galantamine
03
Conditions
tardive dyskinesia (TD)
Beyond the preview
Go deeper on NCT00164242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00164242.